arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

MACROGENICS INC

MGNX
$4.04 ▲ +0.03 (+0.75%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

MACROGENICS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $255.1M
Dividend Yield
Revenue Growth -0.3%
Op. Margin -48.7%
ROIC -129.9%
FCF / Share $-1.31
Trailing P/E
Price / Book 4.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$149.50M
— -0.3%
Net Income Profit after all expenses
$-74.62M
↓ -11.4%
Operating Margin Operating profit as % of sales
-48.7%
↑ +33.9% 5th
FCF / Share Free cash flow per share
$-1.31
↓ -14.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
5
Returns
6
Cash Quality
70

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 57 quarters